1[1]Davies MJ. The composition of coronary-artery plaques[J]. N Engl J Med,1997;336:1312-1314.
2[2]Granger CB, Hirsch J,Califf RM, et o1. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infartion: results from the GUSTO-1 trial[J]. Circulation,1996:93:870-878.
3[3]CAPRIE Steering Committee. A randomised,blinded,trial of clopidogrel versus aspirin in patients at risk of ischaemic events ( CAPRIE ) [ J ]. Lancet, 1996:348:1329-1339.
4[4]Coller BS,Peerschke EI,Scudder LE et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthen-ic-like state in normal platelets and binds to glycoprotein Ⅱ b/Ⅲ a [ J ]. J Clin Invest, 1983:72:325-338.
5[5]The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein Ⅱ b/Ⅲ a in high-risk coronary an, gioplasty [ J ]. N Engl J Med,1994:330:956-961.
6[6]EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein Ⅱb/Ⅲa blockade[J]. Lancet,1998 :352 :87-92.
7[7]EPILOG Investigators. platelet glycoprotein Ⅱ b/Ⅲ a blockade with abciximab with low-dose heparin during percutaneous coronary revascularization [ J ]. N Engl J Med,1997:336:1689-1696.
8[8]CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study [ J ]. Lancet, 1997:349:1429-1435.
9[9]Brener SJ,Barr LA,Burchenal JEB,et al. A randomized,placebo-cotrolled trial of platelet glycoprotein Ⅱ b/M a blockade with primary angioplasty for acute myocardial infarction [ J ]. Circulation, 1998:98:734-741.
10[10]IMPACT II Investigators. Rrandomized placebo-cotrolled trial of effect of eptifibatide on complications of percutaneous coronary intervention:IMPACT Ⅱ[ J ].Lancet, 1997:349:1422-1428.
